BIOTRONIK, a global medical technology company specializing in cardiovascular, endovascular and neuromodulation solutions, has announced the first implantation of its BIOMONITOR IV implantable cardiac monitor (ICM) with artificial intelligence (AI). The device pairs SmartECG technology with AI to reduce false positive detections by 86%, while preserving 98% of true episodes. It is also capable of distinguishing between premature atrial contractions and premature ventricular contractions to provide healthcare professionals with better tools for risk stratification and diagnosis. Other benefits include long battery life, wireless connectivity for remote monitoring and easy electronic health record data integration capability. The procedure was conducted by Luigi Di Biase, MD, PhD at Montefiore Medical Center in New York. This milestone reinforces BIOTRONIK's position as a leading player in the field of cardiac monitoring devices.
Keywords: BIOTRONIK, BIOMONITOR IV, implantable cardiac monitor (ICM), artificial intelligence (AI), SmartECG technology
BIOTRONIK's new implantable cardiac monitor (ICM) pairs SmartECG technology with artificial intelligence to reduce false positive detections by 86%. The device is also capable of distinguishing between different types of contractions to provide healthcare professionals with better